<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Menasché, Philippe</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-21</style></pages><abstract><style  face="normal" font="default" size="100%">The Myoblast Autologous Grafting in Ischemic Cardiomyopathy [MAGIC] Trial examined the safety and efficacy of autologous skeletal myoblast cell therapy for improving local or global cardiac contractility in patients with ischemic heart failure. This is the first multi-center, randomized, double blind and placebo controlled trial of skeletal myoblast implantation and one that is designed with the power sufficient to determine whether autologous grafting is a viable solution for ischemic cardiomyopathy.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>